All News

RA.Ow02.jpg

Rheumatoid Poor Outcomes Not Linked to Comorbidity

d Jack Cush, MD

Disease activity leads to poor outcomes; but does comorbidity add to this?  A recent analysis suggests that while comorbidities do not affect long-term, functional outcomes, sociodemographic factors do affect outcomes in rheumatoid Arthritis (RA).

Read Article
syringe, pill, DMARD, Treatment, therapy

DMARD Effects on COVID-19 Outcomes

d Jack Cush, MD

Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drug

Read Article
RheumNow Podcast square

RheumNow Podcast – World Going to Pot (7.23.2021)

d Jack Cush, MD

Bicycles, Tramadol, biologics - these are but a few of my favorites things in today's broadcast. Join me as I review the news and journal articles from this past week on RheumNow.com.

Read Article
Vertbral,Fracture,spine,compression

Fracture Risk with Low Dose Steroid

d Jack Cush, MD

A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures. 

Read Article
ICYMI: Neuropsychiatric Events Common in Lupus Neuropsychiatric (NP-SLE) or CNS lupus events range from mild to severe; several recent studies have noted that NPS lupus is common and should be screened for. https://t.co/cBDZI8OLKD https://t.co/on4fA3P9GS

Links:

Dr. John Cush RheumNow ( View Tweet)
Fracture Risk with Low Dose Steroid A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures. https://t.co/HcYpx8IDcB https://t.co/iVPjJHLNBX

Links:

Dr. John Cush RheumNow ( View Tweet)
Recent review of the epidemiology of rare Autoimmune Liver disease (PBC, PSC, AIH) shows prevalence (per 100 000) to( vary for PBC (1.91 to 40.2), for PSC (0.78 and 31.7) and for AIH (4.8 to 42.9/100,000) https://t.co/XbRYV5Qlwa

Links:

Dr. John Cush RheumNow ( View Tweet)

Dutch study of 644 t Early Psoriatic Arthritis pts shows that 17% had no psoriasis (PASI = 0), 71% had mild psoriasis (PASI < 7), 9% moderate psoriasis (7–12) and 4% had severe psoriasis (PASI > 12). PASI didnt fluctuate much in 1st year https://t.co/XW3QhJ65Oz

Links:

Dr. John Cush RheumNow ( View Tweet)

#ClinicalPearl Palmar erythema in #SLE #lupus is sometimes painful, may not be fixed and also may have erythema of distal fingers on flexor side https://t.co/C5mysB8pFS
Janet Pope Janetbirdope ( View Tweet)
ICYMI: Metanalysis of Tramadol efficacy & safety in knee or hip #OA. 6 RCTs (3,611 pts) showed little clinical benefit w/ 100/d or 200 mg/d; only 300mg/d was better vs PBO at pain & functional improvement. All doses had higher risk of GI, CNS AEs & W/D https://t.co/wDLHFQWFOe https://t.co/l4B83eUQrW

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: New-Onset IBD & IL-17 Inhibitors: What’s the Risk? https://t.co/zXDQotDiWV Patients w/ inflammatory/autoimmune diseases who initiated treatment w/ IL-17 inhibitors didnt have a higher risk for development of IBD, but only based on the severity of their underlying disease https://t.co/w3IpQkzmn7

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: FDA Approves IVIG in Dermatomyositis https://t.co/BZsl8a6ArW The FDA has approved Octagam 10% [Immune Globulin Intravenous (Human)], as the first and only intravenous immunoglobulin (IVIg) formulation to be approved for adult dermatomyositis (DM). https://t.co/VFF0QMqbin

Links:

Dr. John Cush RheumNow ( View Tweet)
Fracture Risk with Low Dose Steroid https://t.co/HcYpx8IDcB A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures. https://t.co/1bc5nyZUzG

Links:

Dr. John Cush RheumNow ( View Tweet)
Tofacitinib Efficacy in Ankylosing Spondylitis https://t.co/SEKa5OnB50 Deodhar and colleagues have published the results of a study showing that in adult patients with active ankylosing spondylitis (AS), oral tofacitinib was effective (versus placebo) and safe. https://t.co/Wb19EJQZHN

Links:

Dr. John Cush RheumNow ( View Tweet)
Growing Cannabis Use in Arthritis Patients The National Databank for Rheumatic Diseases reports a significant increased in cannabis use amongst arthritis patients between 2014-2019. https://t.co/9YyYB75GuN https://t.co/Xs24kBLmeg

Links:

Dr. John Cush RheumNow ( View Tweet)
New-Onset IBD and IL-17 Inhibitors: What Is the Risk? https://t.co/zXDQotDiWV Patients w/ inflammatory/autoimmune diseases who initiated treatment w/ IL-17 inhibitors didnt have a higher risk for development of IBD, but only based on the severity of their underlying disease https://t.co/hbWf45pQWt

Links:

Dr. John Cush RheumNow ( View Tweet)
Steroid (GC) withdrawal studied in T2T RA cohort of 207 RA pts (F/U 39 mos); Only 60% discontinued GC, w/ low risk of flare. BUT D/Cs were SLOW w/ only 9.7%, 26.6%, 48.0% & 58.6% at 6 mos, 1, 2 & 3 yrs - median time to cessation = 27 mos https://t.co/h02aueYKwN

Links:

Dr. John Cush RheumNow ( View Tweet)

COAST-Y - an extension study of 155 spondyloarthritis pts in remission on ixekizumab; they either continue or had IXE withdrawn. After 40 weeks, 83% on IXE vs 55% of PBO (WD) pts remained flare free. Most flares >20 wks of IXE withdrawal https://t.co/DDzCoFxt0d https://t.co/jgTxFCgQIq

Links:

Dr. John Cush RheumNow ( View Tweet)
Retrospective cohort study of 1719 Psoriasis only pts (F/U 14721 py) were Rx w/ topicals (81%), cDMARDs (13%), bDMARDs (6%). Overall, 239 patients (14%) developed PsA - Lower risk of PSA if Rx w/ biologics (IRR=0.26 vs topicals; not csDMARDs) https://t.co/BqJWPxG7xf

Links:

Dr. John Cush RheumNow ( View Tweet)

Metanalysis of Tramadol efficacy & safety in knee or hip #OA. 6 RCTs (3,611 pts) showed little clinical benefit w/ 100/d or 200 mg/d; only 300mg/d was better vs PBO at pain & functional improvement. All doses had higher risk of GI, CNS AEs & W/D https://t.co/wDLHFQWFOe

Links:

Dr. John Cush RheumNow ( View Tweet)

×